Join to View Full Profile
600 Ridgely AveSte 130Annapolis, MD 21401
Phone+1 410-266-8049
Fax+1 410-266-0895
Dr. Krejci is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kent Krejci is a urology specialist based in Annapolis, MD, with subspecialties in minimally invasive surgery, stone disease, and surgical oncology. He graduated from Lewis Katz School of Medicine at Temple University in 1999 and completed his residency in urology at Mayo Clinic College of Medicine and Science in 2005. His clinical expertise includes urologic oncology, minimally invasive urologic surgery, urologic trauma and reconstructive surgery, and the management of kidney and ureteral stones. Dr. Krejci has contributed to the field through notable publications, such as those on vaccines for urinary tract infections and nephron-sparing surgery, and he has participated in clinical trials on bladder tumors and kidney stones.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Urology, 1999 - 2005
Lewis Katz School of Medicine at Temple UniversityClass of 1999
Certifications & Licensure
MD State Medical License 2006 - 2026
AZ State Medical License 2005 - 2007
WI State Medical License 2005 - 2007
PA State Medical License 2006 - 2006
MN State Medical License 2000 - 2005
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2013-2017
Clinical Trials
- Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones Start of enrollment: 2015 Jul 01
- A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) Start of enrollment: 2015 Oct 09
Publications & Presentations
PubMed
- 44 citationsSafety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results ...Gary R. Eldridge, Heidi Hughey, Lois Rosenberger, Steven M. Martin, Andrew Marc Shapiro
Human Vaccines & Immunotherapeutics. 2021-05-04 - 21 citationsImmunotherapy for Urological MalignanciesKent G. Krejci, Mary A. Markiewicz, Eugene D. Kwon
The Journal of Urology. 2004-02-01 - 42 citationsNephron-sparing surgery for renal cell carcinoma: Clinicopathologic features predictive of patient outcomeKent G. Krejci, Michael L. Blute, John C. Cheville, Thomas J. Sebo, Christine M. Lohse
Urology. 2003-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
